Shanghai-based biotech company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase I study for its small molecule inhibitor, ABSK131. This investigational drug targets PRMT5 and MTA in patients with advanced solid tumors that exhibit MTAP deficiency.
Preclinical Success of ABSK131 in MTAP Deficient Cancer Cells
In preclinical studies, ABSK131 demonstrated excellent selectivity and favorable drug metabolism and pharmacokinetics, particularly towards cancer cells with MTAP deficiency. These promising results have paved the way for the initiation of a Phase I clinical trial to further evaluate the safety, tolerability, and preliminary efficacy of ABSK131 in humans.-Fineline Info & Tech
